VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the subjects with underlying disease at high-risk for worsening COVID-19

Trial Identifier: D8111C00006
Sponsor: AstraZeneca
NCTID:: NCT05084755
Start Date: November 2021
Primary Completion Date: September 2022
Study Completion Date: September 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Akita, Japan
Japan Chiba, Japan
Japan Gunma, Japan
Japan Ibaraki, Japan
Japan Kochi, Japan
Japan Saga, Japan
Japan Saitama, Japan
Japan Shizuoka, Japan
Japan Tokushima, Japan